AVERTS 1

Shares of Otonomy Inc (NASDAQ: OTIC) plummeted more than 80 percent Wednesday morning after the biopharmaceutical company, which focuses on diseases and disorders of the ear, provided a disappointing update to an ongoing clinical trial. Otonomy has been overseeing a Phase 3 trial called AVERTS-1...